214 related articles for article (PubMed ID: 24443159)
1. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.
Wright JD; Ananth CV; Tsui J; Glied SA; Burke WM; Lu YS; Neugut AI; Herzog TJ; Hershman DL
Cancer; 2014 Apr; 120(8):1246-54. PubMed ID: 24443159
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract][Full Text] [Related]
3. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Vogel TJ; Goodman MT; Li AJ; Jeon CY
Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
[TBL] [Abstract][Full Text] [Related]
4. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
5. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
6. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
7. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?
Klein DA; Mann AK; Freeman AH; Liao CI; Kapp DS; Chan JK
Am J Obstet Gynecol; 2020 Feb; 222(2):170.e1-170.e11. PubMed ID: 31421122
[TBL] [Abstract][Full Text] [Related]
9. Racial disparities in the treatment of advanced epithelial ovarian cancer.
Howell EA; Egorova N; Hayes MP; Wisnivesky J; Franco R; Bickell N
Obstet Gynecol; 2013 Nov; 122(5):1025-1032. PubMed ID: 24104782
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
11. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
Seagle BL; Graves S; Strohl AE; Shahabi S
Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
[TBL] [Abstract][Full Text] [Related]
12. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study.
Melamed A; Fink G; Wright AA; Keating NL; Gockley AA; Del Carmen MG; Schorge JO; Rauh-Hain JA
BMJ; 2018 Jan; 360():j5463. PubMed ID: 29298771
[TBL] [Abstract][Full Text] [Related]
13. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
14. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.
Chern JY; Curtin JP
Curr Treat Options Oncol; 2016 Jan; 17(1):1. PubMed ID: 26714493
[TBL] [Abstract][Full Text] [Related]
15. Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis.
Schuurman MS; Kruitwagen RFPM; Portielje JEA; Roes EM; Lemmens VEPP; van der Aa MA
Gynecol Oncol; 2018 May; 149(2):270-274. PubMed ID: 29514738
[TBL] [Abstract][Full Text] [Related]
16. A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
Garcia C; Yao A; Camacho F; Balkrishnan R; Cantrell LA
Gynecol Oncol; 2017 Aug; 146(2):346-350. PubMed ID: 28499649
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer outcomes: Predictors of early death.
Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA
Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531
[TBL] [Abstract][Full Text] [Related]
18. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines.
Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
Obstet Gynecol; 2015 Apr; 125(4):833-842. PubMed ID: 25751200
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer.
Thrall MM; Gray HJ; Symons RG; Weiss NS; Flum DR; Goff BA
Gynecol Oncol; 2011 Dec; 123(3):461-6. PubMed ID: 21945309
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective.
Elstrand MB; Sandstad B; Oksefjell H; Davidson B; Tropé CG
Acta Obstet Gynecol Scand; 2012 Mar; 91(3):308-17. PubMed ID: 22050605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
